Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis Topical formulation of paromomycin ATI-1801 already shown to be safe and effective against the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results